Be sure to catch up on the latest happenings in our spring newsletter here! Nancy Farrugia Related postsIntellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)October 19, 2021Light the Night for Amyloidosis 2025February 20, 20252023 Winter NewsletterFebruary 2, 2023 Previous post2026 Winter Newsletter
